University of Pennsylvania

ScholarlyCommons
Departmental Papers (Dental)

Penn Dental Medicine

1995

Cross-Desensitization of Chemoattractant Receptors Occurs at
Multiple Levels: Evidence for a Role for Inhibition of
Phospholipase C Activity
R. M. Richardson
H. Ali
University of Pennsylvania

E. D. Tomhave
B. Haribabu
R. Snyderman

Follow this and additional works at: https://repository.upenn.edu/dental_papers
Part of the Dentistry Commons

Recommended Citation
Richardson, R. M., Ali, H., Tomhave, E. D., Haribabu, B., & Snyderman, R. (1995). Cross-Desensitization of
Chemoattractant Receptors Occurs at Multiple Levels: Evidence for a Role for Inhibition of Phospholipase
C Activity. Journal of Biological Chemistry, 270 (46), 27829-27833. http://dx.doi.org/10.1074/
jbc.270.46.27829

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/dental_papers/429
For more information, please contact repository@pobox.upenn.edu.

Cross-Desensitization of Chemoattractant Receptors Occurs at Multiple Levels:
Evidence for a Role for Inhibition of Phospholipase C Activity
Abstract
To define the molecular mechanisms of cross-regulation among chemoattractant receptors, we stably
coexpressed, in a rat basophilic leukemia (RBL-2H3) cell line, epitope-tagged receptors for the
chemoattractants formylmethionylleucylphenylalanine (fMLP), a peptide of the fifth component of the
complement system (C5a), and interleukin-8 (IL-8). All the expressed receptors underwent homologous
phosphorylation and desensitization upon agonist stimulation. When co-expressed, epitope-tagged C5a
receptor (ET-C5aR) and epitope-tagged IL-8 receptor (ET-IL-8RA) were cross-phosphorylated by activation
of the other. Activation of epitope- tagged fMLP receptor (ET-FR) also cross-phosphorylated ET-C5aR and
ET-IL- 8RA, but ET-FR was totally resistant to cross-phosphorylation. Similarly, C5a and IL-8 stimulation of
[35S]guanosine 5'-3-P-(thio) triphosphate (GTPγS) binding and Ca2+ mobilization were cross-desensitized
by each other and by fMLP. Stimulation of [35S]GTPγS binding by fMLP was also not cross- desensitized
by C5a or IL-8, however, Ca2+ mobilization was, suggesting a site of inhibition distal to G protein
activation. Consistent with this desensitization of Ca2+ mobilization, inositol 1,4,5-trisphosphate release
in RBL-2H3 cells expressing both ET-C5aR and ET-FR revealed that fMLP and C5a cross-desensitized each
other's ability to stimulate phosphoinositide hydrolysis. Taken together, these results indicate that
receptor cross- phosphorylation correlates directly with desensitization at the level of G protein activation.
The ET-FR was resistant to this process. Of note, cross- desensitization of ET-FR at the level of
phosphoinositide hydrolysis and Ca2+ mobilization was demonstrated in the absence of receptor
phosphorylation. This suggests a new form of chemoattractant cross-regulation at a site distal to
receptor/G protein coupling, involving the activity of phospholipase C.
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To define the molecular mechanisms of cross-regulation among chemoattractant receptors, we stably coexpressed, in a rat basophilic leukemia (RBL-2H3) cell
line, epitope-tagged receptors for the chemoattractants
formylmethionylleucylphenylalanine (fMLP), a peptide
of the fifth component of the complement system (C5a),
and interleukin-8 (IL-8). All the expressed receptors underwent homologous phosphorylation and desensitization upon agonist stimulation. When co-expressed,
epitope-tagged C5a receptor (ET-C5aR) and epitopetagged IL-8 receptor (ET-IL-8RA) were cross-phosphorylated by activation of the other. Activation of epitopetagged fMLP receptor (ET-FR) also cross-phosphorylated ET-C5aR and ET-IL-8RA, but ET-FR was
totally resistant to cross-phosphorylation. Similarly,
C5a and IL-8 stimulation of [35S]guanosine 5*-3-O-(thio)
triphosphate (GTPgS) binding and Ca21 mobilization
were cross-desensitized by each other and by fMLP.
Stimulation of [35S]GTPgS binding by fMLP was also not
cross-desensitized by C5a or IL-8, however, Ca21 mobilization was, suggesting a site of inhibition distal to G
protein activation. Consistent with this desensitization
of Ca21 mobilization, inositol 1,4,5-trisphosphate release
in RBL-2H3 cells expressing both ET-C5aR and ET-FR
revealed that fMLP and C5a cross-desensitized each
other’s ability to stimulate phosphoinositide hydrolysis.
Taken together, these results indicate that receptor
cross-phosphorylation correlates directly with desensitization at the level of G protein activation. The ET-FR
was resistant to this process. Of note, cross-desensitization of ET-FR at the level of phosphoinositide hydrolysis
and Ca21 mobilization was demonstrated in the absence
of receptor phosphorylation. This suggests a new form
of chemoattractant cross-regulation at a site distal to
receptor/G protein coupling, involving the activity of
phospholipase C.

Leukocytes migrate to sites of inflammation where they participate in host-defensive and/or tissue-destructive activities
via activation of chemoattractant receptors. Upon stimulation
by proinflammatory agents such as a peptide component of the
fifth complement system (C5a),1 formylpeptides (fMLP), inter* This work was supported by National Institutes of Health Grant
DE-03738 (to R. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must
therefore be hereby marked “advertisement” in accordance with 18
U.S.C. Section 1734 solely to indicate this fact.
¶ To whom correspondence should be addressed: Depts. of Medicine
and Immunology, Duke University Medical Center, Box 3680, Durham,
NC 27710. Tel.: 919-684-5332; Fax: 919-684-4390.
1
The abbreviations used are: C5a, peptide of the fifth component of
the complement system; fMLP, formylmethionylleucylphenylalanine;

leukin-8 (IL-8), platelet-activating factor, or leukotriene B4
chemoattractant receptors couple to guanine nucleotide binding regulatory proteins (G proteins) to induce cellular responses (1). Prolonged stimulation of these receptors results in
desensitization. Originally, two types of desensitization were
described: homologous and heterologous (2). Homologous desensitization is specific for a receptor and its agonist. Heterologous desensitization refers to a process whereby activation of
one type of receptor results in the desensitization of different
receptors. Homologous desensitization occurs as a result of
phosphorylation of the active form of a receptor by a receptor
kinase, whereas heterologous desensitization affects active
and inactive receptor forms by kinases activated by second
messengers (2, 3).
Cross-desensitization studies of chemoattractant receptors
using Ca21 mobilization as a measurement of receptor activation have led us to the description of a novel type of desensitization whose specificity falls between heterologous and homologous desensitization (4, 21). This type of desensitization was
defined as cross-inhibition of Ca21 mobilization among a particular class of chemoattractant receptors, i.e. those for peptide
but not for lipid chemotactic factors (4, 21). Other studies have
shown that phosphorylation of the cytoplasmic domains of G
protein-coupled receptors, followed by their uncoupling from G
proteins, can be responsible for desensitization (2, 5). However,
experiments in human neutrophils indicated that component(s)
distal from receptor/G-protein may also be involved in chemoattractant receptor cross-desensitization (4). To better define the multiple types of receptor desensitization, we developed a model system, a rat basophilic leukemia cell line (RBL2H3), in which chemoattractant receptors can be expressed and
induced to elicit cellular responses similar to those in neutrophils. Using this model, we recently showed that agonist-stimulation of the chemoattractant receptors for fMLP, C5a, IL-8,
and platelet-activating factor expressed in RBL-2H3 cells resulted in phosphorylation and desensitization of these receptors (6, 7).2 In the present work, we sought to better define the
mechanism(s) of cross-desensitization of chemoattractant receptors. For that purpose, chemoattractant receptors were coexpressed in RBL-2H3 cells and studied for their ability to
undergo and/or mediate cross-phosphorylation and correlate
this with consequent GTPgS binding, generation of inositol
trisphosphates, and mobilization of intracellular calcium. The
results presented here demonstrate that receptor phosphorylET-FR, epitope-tagged fMLP receptor; ET-C5aR, epitope-tagged C5a
receptor; IL-8, interleukin-8; ET-IL-8R, epitope-tagged IL-8 receptor;
IP3, inositol 1,4,5-trisphosphate; GTPgS, guanosine 59-39-O-(thio)triphosphate; G protein, GTP-regulatory protein; PKC, protein kinase C;
PLC, phospholipase C.
2
Richardson, M. R., DuBose, R. A., Ali, H., Tomhave, E., Haribabu,
B., and Snyderman, R. (1995) Biochemistry, in press.
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FIG. 1. Immunoprecipitation of epitope-tagged chemoattractant receptors expressed in RBL-2H3 cells. A, 32P-labeled doubletransfected RBL-2H3 cells (2.5 3 106/60-mm plate) expressing epitope-tagged receptors for FR and C5aR (ET-FCR), IL-8RA and C5aR (ET-ICR),
or IL-8RA and FR (ET-IFR) were incubated for 5 min with (lanes 2, 3, 5, 6, 8, and 9) or without (lanes 1, 4, and 7) stimulants. Cells were lysed,
immunoprecipitated with 12CA5, and analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. This experiment was repeated
five times with similar results. B, RBL-2H3 cells expressing either ET-FR and IL-8RA (lanes 10 –12) or ET-IL-8RA and FR (lanes 13–15) were
stimulated in the presence or absence of either fMLP or IL-8, and receptor phosphorylation was assessed as described above.

ation and modification of a downstream component(s) of the
chemoattractants signaling cascade participate in different
forms of chemoattractant receptor cross-regulation.
EXPERIMENTAL PROCEDURES

Materials—[32P]Orthophosphate (8,500 –9,120 Ci/mmol), myo-[23
H]inositol (24.4 Ci/mmol), and [35S]GTPgS (1300 Ci/mmol) were purchased from DuPont NEN. 125I-IL-8 and [3H]Inositol 1,4,5-trisphosphate (IP3) assay kits were from Amersham. IL-8 (monocyte derived)
was purchased from Genzyme. Monoclonal 12CA5 antibody was from
BabCo. PSV2neo was from American Type Culture Collection. Geneticin (G418) and all tissue culture reagents were purchased from Life
Technologies, Inc. Protein G-agarose and protease inhibitors were from
Boehringer Mannheim. fMLP, indo-1 acetoxymethyl ester, and pluronic
acid were from Molecular Probes. C5a, GDP, GTP, GTPgS, and ATP
were purchased from Sigma. Thapsigargin and ionomycin were from
Calbiochem. All other reagents were from commercial sources.
Construction of Epitope-tagged Receptors—Nucleotides encoding a
nine-amino acid epitope sequence (YPYDVPDYA) was inserted between
the N-terminal initiator methionine and the second amino acid of each
cDNA by polymerase chain reaction as described previously (6, 7).2
Cell Culture and Transfection—RBL-2H3 cells were maintained as
monolayer cultures in Earle’s modified Eagle’s medium supplemented
with 15% fetal bovine serum, 2 mM glutamine, penicillin (100 units/ml),
and streptomycin (100 mg/ml) (6). These cells (1 3 107 cells) were
transfected by electroporation with either pRK5 or pCDNA3 containing
the receptor cDNAs (20 mg). Geneticin-resistant cells were selected by
subculturing the transfected cells in growth medium supplemented
with geneticin (1 mg/ml), and cell surface expression of the receptors
was monitored by fluorescence-activated cell sorter analysis as described previously (6, 7).2 For double transfectants, RBL-2H3 cells
expressing one receptor were electroporated in the presence of pRK5
vectors (20 mg) containing the second receptor cDNA. Double transfectants were isolated by fluorescence-activated cell sorter using fluorescein isothiocyanate ligand for the second receptor. The receptors coexpressed in RBL-2H3 cells displayed pharmacological and functional
properties similar to those obtained with single expression of the receptors (Kd values were ;80 nM, ;8 pM, ;2 nM for ET-FR, ET-C5aR,
and ET-IL-8RA, respectively) (6, 7).2
Phosphorylation of the Epitope-tagged Receptors—Phosphorylation of
ET receptors was performed as described previously (6, 7).2 Briefly,
RBL-2H3 cells (2.5 3 106) expressing each combination of receptors
were subcultured overnight in 60-mm tissue culture dishes. The following day, the cells were rinsed twice with 5 ml of phosphate-free Dulbecco’s modified Eagle’s medium and incubated in the same medium
supplemented with [32P]orthophosphate (150 mCi/dish) for 90 min to
metabolically label the intracellular ATP pool. Then, labeled cells were
stimulated with or without agonists (IL-8, 100 nM; C5a, 100 nM; or
fMLP, 1 mM) for 5–7 min at 37 °C. The phosphorylated receptors were
immunoprecipitated with the 12CA5 antibody, analyzed by SDS-electrophoresis, and visualized by autoradiography (6, 7).2
GTPgS Binding—Cells were treated with appropriate concentrations of stimulants, and membranes were prepared as already described
(7).2 [35S]GTPgS binding, using 10 –20 mg of membrane preparations,

was carried out as described previously.2
Calcium Measurement—Cells (3 3 106) were removed, washed with
HEPES-buffered Hank’s balanced salt solution, and loaded with 1 mM
indo I-acetoxymethyl ester in the presence of 1 mM pluronic acid for 30
min at room temperature. Then, the cells were washed and resuspended in 1.5 ml of buffer. Intracellular calcium increase in the presence of different ligands at the indicated doses (fMLP, 100 nM; C5a, 10
nM; IL-8, 10 nM) was measured as described (6).
Inositol Phosphate Extraction and Measurement—RBL-2H3 cells expressing both ET-FR and ET-C5aR were plated in 60-mm dishes (2.5 3
106 cells/dish) and equilibrated in serum-free medium for 1 h. Cells
were then treated with or without agonists in the same medium at
37 °C. The reactions were terminated by addition of an equal volume of
ice-cold 15% (w/v) trichloroacetic acid, and the samples were kept on ice
for 30 min. Inositol phosphates were extracted three times with 10
volumes of water-saturated diethyl ether and neutralized to pH 7.5
with 1 M NaHCO3 (9). 50 ml of each extract was used to determine the
IP3 mass using the Amersham radioreceptor binding assay kit.
RESULTS

Phosphorylation and Immunoprecipitation of ET Receptors
in RBL-2H3 Cells—RBL-2H3 cells expressing epitope-tagged
receptors for FR and C5aR, IL-8RA and C5aR, or FR and
IL-8RA were 32P labeled and treated with different ligands (1
mM fMLP, 0.1 mM C5a, or 0.1 mM IL-8) and immunoprecipitated
with 12CA5 antibody. As shown in Fig. 1, ET-C5aR (;45 kDa)
was phosphorylated by C5a (lanes 3 and 6) and cross-phosphorylated by fMLP (lane 2) and IL-8 (lane 5). ET-IL-8RA (;70
kDa) was phosphorylated by IL-8 (lanes 5 and 8) and crossphosphorylated by C5a (lane 6) and fMLP (lane 9). In contrast,
ET-FR (;65 kDa) was phosphorylated by fMLP (lanes 2 and 9)
but resistant to cross-phosphorylation by either C5a (lane 3) or
IL-8 (lane 8) stimulation. The identity of these phosphorylated
bands as the respective receptors has been previously demonstrated by immunoprecipitation of iodinated and phosphorylated receptors in the presence and absence of the epitope tag
peptide (6).2 Since ET-IL-8RA and ET-FR migrate as broad
overlapping bands in these SDS gels, double-transfected RBL2H3 cell lines with one wild type and the other epitope-tagged
receptors were prepared to more clearly resolve cross-phosphorylation of these two receptors. As shown in Fig. 1B, RBL-2H3
cells expressing ET-IL-8RA and wild type FR and vice versa
showed similar results to ET-IFR cells when stimulated with
either IL-8 (0.1 mM) (Fig. 1B, lanes 11 and 14) or fMLP (1 mM)
(Fig. 1B, lanes 12 and 15).
We also determined whether ligand cross-reactivity could
result in an apparent receptor cross-phosphorylation. Single
transfected RBL-2H3 cells expressing either ET-C5aR or ETIL-8RA were 32P labeled, treated with C5a (0.1 mM), IL-8
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FIG. 2. Homologous and cross-desensitization of peptide chemoattractant receptors stimulated [35S]GTPgS binding. Doubletransfected RBL-2H3 cells were treated with fMLP (1 mM), C5a (100
nM), or IL-8 (100 nM) for 5 min. Membranes were prepared and assayed
for agonist-stimulated [35S]GTPgS binding. The data shown are the
means of three different experiments performed in triplicate. The values are represented as percentage of maximum stimulation, which is
defined as the maximal increase above basal of [35S]GTPgS bound to
control membranes (untreated cells) after 10 min of reaction. Basal
activities were ;0.2– 0.3 pmol of [35S]GTPgS bound/mg of protein).
Maximum stimulation was 0.23 6 0.008 (fMLP) and 0.19 6 0.010 (C5a)
pmol of 35S-GTPgS bound/mg of protein for untreated ET-FCR cells
(panel A), 0.2 6 0.011 (C5a) and 0.21 6 0.02 (IL-8) pmol of [35S]GTPgS
bound/mg of protein for untreated ET-ICR cells (panel B), and 0.19 6
0.008 (fMLP) and 0.22 6 0.0132 (IL-8) pmol of [35S]GTPgS bound/mg of
protein for untreated ET-IFR cells (panel C). Specific activity was
;380 – 450 cpm/fmol of GTPgS.

(0.1 mM), or fMLP (1 mM), and immunoprecipitated. Only homologous phosphorylation was observed for each receptor (i.e.
ET-C5aR only by C5a and ET-IL-8RA only by IL-8) (data not
shown), indicating that ligand cross-reactivity does not occur in
these receptors.
GTPgS Binding in Cross-desensitized Membranes—To determine the effect of cross-phosphorylation in receptor cross-desensitization, agonist-stimulated [35S]GTPgS binding was
measured in membranes prepared from double transfectant
RBL-2H3 cells pretreated with fMLP (1 mM), C5a (100 nM), or
IL-8 (100 nM). As shown in Fig. 2, pretreatment of cells with
fMLP (A and C), C5a (A and B), or IL-8 (B and C) resulted in
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homologous desensitization (50 –70%) of agonist-induced
[35S]GTPgS binding to membranes. Membranes from cells pretreated with fMLP (ET-FCR (Fig. 2A) and ET-IFR (Fig. 2C))
showed a ;40 and ;22% decrease in C5a and IL-8-stimulated
[35S]GTPgS binding, respectively, whereas no decrease was
observed for fMLP stimulation in cells pretreated with either
C5a or IL-8 (Fig. 2, A and C). Both, ET-C5aR and ET-IL-8RA
cross-desensitized (;28 and ;25%, respectively) each other’s
ability to stimulate [35S]GTPgS binding in ET-ICR cells pretreated with either C5a or IL-8 (Fig. 2B).
Cross-desensitization of Receptor-induced Ca21 Mobilization—Ca21 mobilization was also measured to determine the
relationship between cross-phosphorylation and cross-desensitization of receptor-mediated cellular responses. As shown in
Fig. 3, all three receptors induced Ca21 mobilization in response to agonist stimulation. Ca21 mobilization in response to
an EC100 dose of fMLP (100 nM), C5a (10 nM), or IL-8 (10 nM)
was homologously desensitized by a first dose of the same
ligand (data not shown). C5a-induced Ca21 mobilization was
cross-desensitized by pretreatment of the cells with a first dose
of either fMLP (Fig. 3A) or IL-8 (Fig. 3B). IL-8-induced Ca21
mobilization was similarly cross-desensitized by pretreatment
of the cells with a first dose of either C5a (Fig. 3B) or fMLP (Fig.
3C). However, in contrast to fMLP-stimulated [35S]GTPgS
binding, fMLP-induced Ca21 mobilization was also cross-desensitized by pretreatment of the cells with a first dose of either
C5a (Fig. 3A) or IL-8 (Fig. 3C).
It was determined whether a depletion of the intracellular
calcium pool caused by the first ligand could account for the
attenuation of Ca21 mobilization in response to a second stimuli. Treatment of ET-FCR cells with 2 mM thapsigargin before
stimulation (301 6 21 nM), 3 min after the first ligand (362 6
13 nM) and after the second ligand (388 6 17 nM), followed by 10
mM ionomycin (621 6 76 nM) showed no significant change in
the intracellular Ca21 pool. These results indicate that the
cross-desensitization of receptor-mediated Ca21 mobilization
was not due to an impairment of the intracellullar Ca21
storage.
Cross-desensitization of Receptor-mediated IP3 Generation—
The ability of fMLP and C5a to stimulate PIP2 hydrolysis in
control versus desensitized cells was determined by measuring
the intracellular concentration of IP3. As shown in Fig. 4,
pretreatment of RBL-2H3 cells expressing both fMLPR and
C5aR with an EC100 dose of either fMLP (1 mM) or C5a (100 nM)
decreased by 85–95% the ability of the receptors to mediate
intracellular increase of IP3 levels.
DISCUSSION

Despite a large body of evidence indicating that chemoattractant-mediated inflammatory responses are regulated by desensitization, little is known about the molecular events governing
this process. Wilde et al. (10) reported that C5a-stimulated
GTPase activity was desensitized in membranes from neutrophils pretreated with fMLP. These results were confirmed by
our previous work, which further indicated that exposure of
neutrophils to fMLP cross-desensitized C5a, IL-8, platelet-activating factor, and leukotriene B mediated-GTPgS binding in
membranes. In contrast, receptors for formylpeptide were resistant to this type of cross-desensitization due presumably to
the absence of the necessary phosphorylation site (see below)
(4). Heterologous phosphorylation of chemoattractant receptors
by second messenger-activated kinases (such as PKC) followed
by their uncoupling from G protein has been thought to be the
molecular mechanism responsible for chemoattractant crossdesensitization (4, 6). However, Tardif et al. (11) reported that
fMLP stimulation of HL-60 cells did not induce C5aR phosphorylation. The data presented in the work reported here clearly
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FIG. 3. Cross-desensitization of chemoattractant receptors mediated Ca21 mobilization. Double-transfected RBL-2H3 cells (3 3 106
cells/assay) were loaded with indo-1 and stimulated with fMLP (100 nM), C5a (10 nM), or IL-8 (10 nM). Cells were rechallenged 3 min later with
the same concentration of ligand. Traces are representative of three experiments.

FIG. 4. Measurement of IP3 concentration in control and desensitized RBL-2H3 cells. RBL-2H3 cells (2.5 3 106 cells) expressing
epitope-tagged FR and C5aR were treated with 1 mM fMLP (fMLPtreated), 100 nM C5a (C5a-treated), or in the absence of stimulants
(untreated cells) for 10 min at 37 °C in serum-free medium. Cells were
then rechallenged for 10 s with fMLP, C5a, or buffer, and IP3 was
extracted as described under “Experimental Procedures.” The IP3 concentration in each extract was determined using the IP3 3H assay
system from Amersham. Data are means 6 S.E. of four separate determinations performed in duplicate.

indicate that fMLP stimulation resulted in phosphorylation of
both C5aR and IL-8RA in double-transfected RBL-2H3 cells
(Fig. 1), and both C5a and IL-8-mediated GTPgS binding were
desensitized under such conditions. The failure of Tardif et al.
(11) to find such cross-phosphorylation in HL-60 cells is not
understood.
The extent of fMLP-mediated phosphorylation of ET-C5aR
and ET-IL-8RA mirrored the ones previously obtained upon
exposure of these receptors to the protein kinase C activator,
phorbol 12-myristate 13-acetate (6, 7).2 These results suggest
that fMLP cross-desensitization of ET-C5aR and ET-IL8RA, as
well as C5a of ET-IL8RA and IL-8 of ET-C5aR, may be mediated by receptor phosphorylation by PKC. Indeed, the PKC
inhibitor staurosporine inhibited fMLP-mediated phosphorylation of ET-C5aR in the ET-FCR cell line (data not shown).
fMLP has been shown to increase PKC activity in neutrophils

and several other cell lines (12–14). Molecular cloning has
revealed that the receptor for fMLP lacks sequence motif for
PKC phosphorylation (RXXSXRX). This likely explains its resistance to PKC-mediated phosphorylation (15). Neither C5a
nor IL-8 pretreatment resulted in cross-desensitization of
fMLP-mediated GTPgS binding, which correlated with its resistance to cross-phosphorylation. Taken together, these results are in agreement with the current concept that receptor
phosphorylation leads to desensitization and indicate that
PKC-mediated phosphorylation results in one form of chemoattractant receptor cross-desensitization at the level of receptor/G protein activation.
Interestingly, receptor cross-phosphorylation cannot explain
the cross-desensitization of formylpeptide receptor-mediated
Ca21 mobilization by other chemoattractants since the
formylpeptide receptors are totally resistant to the heterologous phosphorylation. Thus, the formylpeptide receptors provide an important tool to determine the downstream site(s) for
chemoattractant receptor cross-desensitization. The chemoattractant receptors studied here are coupled to phospholipase C
and mediate intracellular signals via stimulation of phosphatidylinositol hydrolysis and production of IP3 and diacylglycerol
(1). It has been shown that IP3 plays a pivotal role in stimulating intracellular Ca21 mobilization (16). Thus, cross-desensitization of fMLP-mediated Ca21 mobilization could be at the
level of PIP2 hydrolysis or IP3 activity. Indeed, cAMP-mediated
phosphorylation of the receptor for intracellular generated IP3
markedly decreases its ability to stimulate Ca21 release (17).
Therefore, the possibility existed that cross-desensitization of
fMLP-induced intracellular Ca21 mobilization reflected either
a decrease in the level of intracellular IP3 produced or desensitization of the receptor for IP3. As shown in fig. 4, fMLP
stimulated IP3 production was decreased by ;90% in cells
pretreated with C5a. These results indicate that the crossdesensitization of Ca21 mobilization in response to fMLP by the
other chemoattractants is likely due to a decrease in the level
of IP3 production. There are several possible explanations for
diminished IP3 production. A depletion of the pool of PIP2 prior
hydrolysis or stimulation of phosphatidylinositol-3 kinase ac-
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tivity is one explanation. Against this hypothesis is that pretreatment of neutrophils with C5a decreased fMLP-induced IP3
production with no significant change in the level of PIP2 (18).
Moreover, in neutrophils that have been cross-desensitized by
fMLP, purinergic receptor ability to stimulate PLC and Ca21
release is normal, indicating adequate IP3 receptor and PIP2
level (4). A second explanation for diminished IP3 production is
a decrease in the catalytic activity of the phospholipase C
either by modification of the enzyme or its activating components. Both a and bg subunits of G protein have been shown to
activate PLC in reconstituted systems (19). Chemoattractant
receptors couple to Gi and mediate PLCb2 activation via Gbg
subunits (1, 19). g subunits are known to be isoprenylated and
methylated (20). It has recently been shown that demethylation of the bg subunit, which does not affect receptor-mediated
GTPgS binding to G protein, caused a 10-fold decrease in
bg-mediated activation of PLC and, thus, production of IP3 (8).
Therefore, it is possible that C5a and IL-8-mediated crossdesensitization of FR-induced Ca21 mobilization may be due to
either a demethylation or other modification of bg subunits,
rendering them less effective in activating PLC. Modification of
PLC itself could also result in its diminished activity. In any
case, the cross-desensitization of formylpeptide receptor as presented is likely due to a modification in its ability to activate
PLC. C5a- and IL-8-induced Ca21 mobilization and IP3 production are also inhibited in cells pretreated with fMLP. Since all
three chemoattractant receptors studied here apparently utilize the same signal transduction pathways, the downstream
effect observed with the fMLP receptor likely plays a role in the
attenuation of C5a- and IL-8-induced responses in addition to
the impairment of receptor/G protein coupling due to receptor
phosphorylation.
In summary, we have developed a system to stably co-express two G protein-coupled receptors and study their crossregulation. The results presented herein indicate that chemoattractant receptor-mediated inflammatory response are
regulated at multiple sites. One is at the level of receptor
phosphorylation affecting receptor/G protein coupling. The sec-
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ond is at a site distal to that, presumably involving the activity
of phospholipase C. Cross-desensitization at different levels of
the signaling cascades may be used by the receptors to control
each other’s activity at sites of inflammation where multiple
chemoattractants are present. It will be important to determine if receptor cross-desensitization at the level of PLC occurs
more generally than the subgroup of chemoattractant receptors
studied here.
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